过去一年中添加的文章，按日期排序
[PDF][PDF] Neoadjuvant osimertinib: a promising therapeutic option for locally advanced EGFR-mutant lung adenocarcinoma
S Yuhara, Y Shimada, M Sato - AME Clinical Trials Review, 2024 - cdn.amegroups.cn
56 天前 - … the patients had treatment-related adverse events of grade 3, demonstrating the
promising efficacy and … efficacy of neoadjuvant erlotinib compared with standard chemotherapy, …
promising efficacy and … efficacy of neoadjuvant erlotinib compared with standard chemotherapy, …
578P Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute …
LJ Hung, JWC Chang, CY Huang, YF Fang… - Annals of …, 2023 - annalsofoncology.org
203 天前 - … metastasis, efficacy and safety of EGFR-TKIs were compared. … ≥3 adverse events
than those treated with gefitinib and … better efficacy than gefitinib or erlotinib in elderly patients …
than those treated with gefitinib and … better efficacy than gefitinib or erlotinib in elderly patients …
… score matching analysis for osimertinib versus comparator first-generation EGFR tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR …
D Zhang, X Liu, F Shen, D Zhao, Y Shi… - Annals of …, 2023 - annalsofoncology.org
234 天前 - … trial compared osimertinib with either erlotinib or gefitinib in the first… Most adverse
events were mild and there were no … study aim to present safety as well as preliminary efficacy. …
events were mild and there were no … study aim to present safety as well as preliminary efficacy. …
Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic …
W Chen, J Miao, Y Wang, W Xing, X Xu… - Frontiers in …, 2023 - frontiersin.org
336 天前 - … adverse events (AE), occurrence of adverse events of grade 3 or above (≥3AE),
and occurrence of serious adverse events (… The highest-ranking therapies were erlotinib (Erl) …
and occurrence of serious adverse events (… The highest-ranking therapies were erlotinib (Erl) …
Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with …
YL Wu, Q Zhou, J Wang, Y Yu, L Xing, Y Wang… - 2023 - ascopubs.org
357 天前 - … superior systemic and IC antitumor efficacy compared with first generation EGFR
TKIs in pts with EGFRm + NSCLC and CNS metastasis. Adverse events were as expected and …
TKIs in pts with EGFRm + NSCLC and CNS metastasis. Adverse events were as expected and …
Clinical efficacy analysis of furmonertinib and structural insights into sensitivity to diverse TKIs for NSCLC with EGFR exon 20 insertion.
X Zhang, G Feng, B Liu, H Han, B Dong, Y Yang, H Zhu… - 2023 - ascopubs.org
357 天前 - … Comparative analysis of the efficacy of different groups showed that median PFS
was … No grade 3 or above adverse events were observed. Furthermore, rather than erlotinib (…
was … No grade 3 or above adverse events were observed. Furthermore, rather than erlotinib (…